Related Experiment Video
Updated: Aug 12, 2026
Treatment with Vancomycin Loaded Calcium Sulphate and Autogenous Bone in an Improved Rabbit Model of Bone Infection
Published on: March 14, 2019
[Chronic recurrent multifocal osteomyelitis: report of five cases]
S Guillén Martín1, S Belda Hofheinz, P Rojo Conejo
1Unidad de Niños Pequeños e Inmunodeficiencias, Departamento de Pediatría, Hospital 12 de Octubre, Madrid, España. saraguillen@wanadoo.es
Abstract:
Chronic recurrent multifocal osteomyelitis is a rare disease of unknown etiology that mainly affects children. We present a retrospective review of the medical records of five patients with a diagnosis of chronic recurrent multifocal osteomyelitis in an infectious diseases clinic at a tertiary center. We describe the epidemiological, clinical and radiological features, laboratory, microbiological and histological findings, treatment, course and prognosis in these patients. There is no specific treatment for chronic recurrent multifocal osteomyelitis. There are new treatment options such the combination of azithromycin and calcitonin in children without clinical improvement with non-steroidal anti-inflammatory drugs.
Insights
Chronic recurrent multifocal osteomyelitis (CRMO) is a rare pediatric bone disease. New treatments like azithromycin and calcitonin show promise for children unresponsive to NSAIDs.
Area of Science:
- Pediatric Rheumatology
- Pediatric Infectious Diseases
- Pediatric Orthopedics
Background:
- Chronic recurrent multifocal osteomyelitis (CRMO) is a rare, painful inflammatory bone condition primarily affecting children.
- Its etiology remains largely unknown, presenting diagnostic and therapeutic challenges.
Observation:
- This study reviews five pediatric CRMO cases managed at a tertiary infectious diseases clinic.
- Data collected included epidemiological, clinical, radiological, laboratory, microbiological, and histological findings.
Findings:
- CRMO management lacks a specific treatment protocol.
- A combination of azithromycin and calcitonin emerged as a potential therapeutic option for children with persistent symptoms despite non-steroidal anti-inflammatory drug (NSAID) treatment.
Implications:
- This case series highlights the need for further research into CRMO pathogenesis and treatment optimization.
- Exploring novel therapeutic strategies like azithromycin-calcitonin combinations may improve outcomes for affected children.
